Item 10. Directors and Executive Officers of the Registrant



(a)  Identification of Directors.


Incorporated by reference to the Company's definitive Proxy Statement in
connection with its 2001 Annual Meeting of Shareholders to be held on April 24,
2001, which Proxy Statement has been filed pursuant to Regulation 14A under the
Securities and Exchange Act of 1934, as amended.


(b)  Identification of Officers.


Christopher A. Kuebler, 47, has been Covance's President and Chief Executive
Officer since November 1994. From March 1993 through November 1994, he was the
Corporate Vice President, European Operations for Abbott Laboratories Inc.
("ALI"), a diversified health care company. From January 1991 until March 1993,
Mr. Kuebler was the Vice President, Sales and Marketing for ALI's Pharmaceutical
Division. Mr. Kuebler has been a member of the Covance Board since
November 1994, and was elected Chairman in November 1996.


William E. Klitgaard, 47, has been Covance's Corporate Senior Vice
President, Chief Financial Officer and Treasurer since September 2000. From
September 1999 to September 2000, Mr. Klitgaard had been Covance's Corporate
Vice President, Strategy and Corporate Development and Treasurer. From
October 1996 to September 1999, Mr. Klitgaard was Covance's Corporate Vice
President and Treasurer. Prior to that, Mr. Klitgaard was Treasurer at Kenetech
Corporation in San Francisco, and prior to that Mr. Klitgaard spent eleven years
in positions of increasing responsibility with Consolidated Freightways Inc.


Michael Giannetto, 38, has been Covance's Controller since July 1996 and a
Corporate Vice President since February 1998. From November 1996 to
February 1998, Mr. Giannetto was a Vice President of Covance. From March 1995 to
July 1996, Mr. Giannetto was the Business Controller for Covance. From
December 1992 to March 1995, Mr. Giannetto was the Manager of Financial
Reporting and Technical Accounting for Corning Life Sciences Inc., an affiliate
of the Company prior to December 31, 1996. Prior to December 1992, Mr. Giannetto
was a Senior Audit Manager for Deloitte & Touche.


Charles C. Harwood, Jr., 47, has been Covance's Corporate Senior Vice
President-Venture Development since May 2000. Mr. Harwood was Covance's
Corporate Senior Vice President and Chief Financial Officer from July 1996 to
May 2000. From November 1994 to July 1996, Mr. Harwood was Covance's Vice
President and Chief Financial Officer. From May 1993 to November 1994,
Mr. Harwood was Executive Director, Finance of Covance. From January 1993 to
May 1993, Mr. Harwood was Chief Financial Officer and Vice President of Finance
with Integrated Telecom Technologies, Inc. Prior to January 1993, Mr. Harwood
worked for seven years in the field of commercial real estate development and
six years with the Hewlett-Packard Company in its Medical Products Division.
Mr. Harwood is director of the Mid-Atlantic Permanente Medical Group, the
for-profit physician group serving the Mid-Atlantic region of the Kaiser
Permanente health plan.


Joseph L. Herring, 45, has been Covance's Corporate Senior Vice President
and President-Early Development Services since September 1999. From
September 1996 to September 1999, Mr. Herring was Corporate Vice President and
General Manager of Covance Laboratories North America. Prior to joining Covance,
Mr. Herring was Vice President of Caremark International, a provider of home
care and physician practice management services.


Alan Horgan, 44, has been Covance's Corporate Senior Vice President and
President-Clinical Development Services since September 1999. From November 1997
to September 1999, Mr. Horgan was Corporate Vice President and General Manager
of Covance Clinical Development Services Europe. From May 1996 to
September 1997, Mr. Horgan was Managing Director of Nutraceuticals, Ltd., and
from September 1996 to March 1997 was Interim CEO of Lotus Healthcare, a
pharmaceutical company based in Beijing PRC. From 1994 to 1996, Mr. Horgan was
Managing Director UK Operations of Fisons, a multinational pharmaceutical
company. Mr. Horgan was Managing Director of Boot Pharmaceuticals, Ltd. from
1991 to 1994. Prior to this, he was at ER Squibb & Sons/Bristol-Myers Squibb
from 1980 in a variety of sales, marketing and general management roles.


Howard Moody, 50, joined Covance in February 2000, as Corporate Senior Vice
President-Chief Information Officer. Prior to joining Covance, Mr. Moody was
Vice President, Information Systems, Core Business for Quest Diagnostics Inc., a
position to which Mr. Moody was appointed after Smithkline Beecham Clinical
Laboratories was acquired by Quest in 1999. Mr. Moody held that position with
Smithkline Beecham Clinical Laboratories from 1995 to 1999. From 1989 to 1995
Mr. Moody held various positions of increasing responsibility with Smithkline
Beecham.



42





F. John Mills, M.D., Ph.D., 49, has been Covance's Corporate Senior Vice
President and President-Clinical Support Services since September 1999. From
March 1999 to September 1999, Dr. Mills was Corporate Vice President and Global
General Manager of Covance Central Laboratory Services Inc. From September 1997
to March 1999, Dr. Mills was Corporate Vice President and General Manager of
Covance Central Laboratory Services Inc. From January 1997 to September 1997,
Dr. Mills was Corporate Vice President and General Manager of Covance CAPS
Europe. From 1992 to January 1997, Dr. Mills was Corporate Vice President and
General Manager of CAPS Europe for Covance.


Stephen J. Sullivan, 54, joined Covance in June 1999 and has been Covance's
Corporate Senior Vice President and President-Clinical Development and Support
Services since September 1999. From 1996 to 1999, Mr. Sullivan was Chairman of
the Board, President and Chief Executive Officer of Xenometrix, Inc., a Boulder,
Colorado-based biotechnology company. Prior to that, Mr. Sullivan was Vice
President, Worldwide Marketing for the Diagnostics Division, and Vice President
and General Manager of the Diagnostic Assay Sector of Abbott Laboratories.
Mr. Sullivan continues to serve as Chairman of the Board of Xenometrix, Inc.